Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade

被引：27
|
作者：
Mittal, Deepak [1 ]
Vijayan, Dipti [1 ]
Smyth, Mark J. [1 ]
机构：
[1] QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld, Australia
来源：
CANCER DISCOVERY | 2018年 / 8卷 / 09期
关键词：
THERAPY; CELLS;
D O I：
10.1158/2159-8290.CD-18-0798
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy. (C) 2018 AACR.
引用
收藏
页码：1066 / 1068
页数：3
相关论文
共 50 条
  • [1] CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis.
    Chen, Limo
    Byers, Lauren Averett
    Ullrich, Stephen
    Wistuba, Ignacio Ivan
    Qin, Xiao-Feng
    Gibbons, Don Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [2] Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Shergold, Amy L.
    Millar, Rhona
    Nibbs, Robert J. B.
    PHARMACOLOGICAL RESEARCH, 2019, 145
  • [3] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [4] Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
    Wang, Qiaohong
    Wu, Xia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 46 : 210 - 219
  • [5] Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Nowicki, Theodore S.
    Hu-Lieskovan, Siwen
    Ribas, Antoni
    CANCER JOURNAL, 2018, 24 (01): : 47 - 53
  • [6] Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles
    Deng, Jun
    Ke, Hui
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [7] CD38-Mediated Immunometabolic Suppression as a Mechanism of Resistance to PD-1/PD-L1 Axis Blockade
    Chen, L.
    Diao, L.
    Yang, Y.
    Yi, X.
    Rodriguez, B. L.
    Li, Y.
    Rodriguez-Canales, J.
    Liu, X.
    Huang, A.
    Zhao, Q.
    Peng, D.
    Fradette, J.
    Tong, P.
    Ungewiss, C.
    Fan, Y.
    Peng, D.
    Villalobos, P.
    Dmitrovsky, E.
    Papadimitrakopoulou, V.
    Wang, J.
    Byers, L. A.
    Heymach, J.
    Ullrich, S.
    Wistuba, I.
    Qin, X.
    Gibbons, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1779 - S1779
  • [8] Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
    Pathak, Ranjan
    Pharaon, Rebecca R.
    Mohanty, Atish
    Villaflor, Victoria M.
    Salgia, Ravi
    Massarelli, Erminia
    CANCERS, 2020, 12 (12) : 1 - 13
  • [9] Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
    Cheng, Chao
    Zhuge, Lingdun
    Xiao, Xin
    Luan, Siyuan
    Yuan, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome
    Zou, R.
    Wang, Y.
    Ye, F.
    Zhang, X.
    Wang, M.
    Cui, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (11): : 2237 - 2252
12345